HydroGraph’s Graphene selected by Hawkeye Bio for use in its early-stage lung cancer detection biosensor

HydroGraph Clean Power has announced that its flagship graphene product, FGA-1, has been successfully trialed in Hawkeye Bio’s biomedical sensor aimed at the early detection of lung cancer. Hawkeye Bio is a clinical stage medical technology company focused on the early detection of cancer.

HydroGraph’s graphene was selected by Hawkeye Bio based on the purity and consistency of its graphene. Headquartered in Toronto, HydroGraph’s manufacturing facility is located in Manhattan, Kan.

Read the full story Posted: Jan 03,2024

Zentek launches Triera Biosciences

Canada-based Zentek has announced the launch of Triera Biosciences as its wholly owned subsidiary for its aptamer platform technology. This subsidiary now owns the exclusive, global licensing rights for all aptamer-based technology from the collaboration with McMaster University.

The Company is repotedly taking this action following the strong, consistent pre-clinical results of its universal aptamer as a treatment against the SARS-CoV-2 virus including the latest Omicron XBB 1.5 variant and will continue to build upon its previous work on a rapid detection platform within the new subsidiary. Triera will offer a pure play in the biotech space when operated as an independent business and be more accessible to potential pharmaceutical partners, funders, and other interested parties.

Read the full story Posted: Dec 15,2023

Researchers develop DNA aptamer-attached portable graphene biosensor for the detection of degenerative brain diseases

An international team of researchers, including scientists from University of California San Diego, Chinese Academy of Sciences, University of Texas Medical Branch and University of Illinois Urbana-Champaign, has developed a handheld, non-invasive graphene-based device that can detect biomarkers for Alzheimer’s and Parkinson’s Diseases. The biosensor can also transmit the results wirelessly to a laptop or smartphone.

The biosensor consists of a chip with a highly sensitive transistor, made of a graphene layer that is a single atom thick and three electrodes–source and drain electrodes, connected to the positive and negative poles of a battery, to flow electric current, and a gate electrode to control the amount of current flow. Image credit: UCSD

The team tested the device on in vitro samples from patients. The tests reportedly showed the device is as accurate as other state-of-the-art devices. Ultimately, researchers plan to test saliva and urine samples with the biosensor. The device could be modified to detect biomarkers for other conditions as well.

Read the full story Posted: Nov 16,2023

IIT Guwahati researchers advance the use of modified graphene oxide in biomedical applications

Researchers at the Indian Institute of Technology (IIT) Guwahati have developed cost-effective experiments for modifying graphene oxide (GO) that can be used by other academic institutions to train personnel needed for cutting-edge projects in semiconductors, nanoelectronics, healthcare and quantum technologies.

A team led by Rajiv K Kar, assistant professor, at the Jyoti and Bhupat Mehta School of Health Sciences and Technology in IIT-Guwahati, made these discoveries regarding the use of modified graphene oxide for biomedical applications, according to a recent announcement.

Read the full story Posted: Nov 08,2023

Archer Materials demonstrates multiplexing readout for its Biochip gFET

Archer Materials, a semiconductor company advancing the quantum computing and medical diagnostics industries, has demonstrated multiplexing readout for its advanced Biochip graphene field effect transistor (“gFET”) device.

Archer confirmed single-device multiplexing using four advanced gFETs as sensors, which were integrated into the Archer advanced Biochip platform. This is significant as Archer intends to apply its multiplexing capability in the Biochip to test for multiple diseases on a single chip at once.

Read the full story Posted: Nov 03,2023

A new Horizon Europe project called 2D-BioPAD is launched

2D-BioPAD is the name of a new Horizon Europe project that was recently launched. With a nearly €6 million budget, 2D-BioPAD will develop a diagnostic system for early Alzheimer's disease detection. This Horizon Europe Research and Innovation Action funded by the European Union, officially commenced on October 2023 and will go on for 48 months.

2D-BioPAD is developing a fast, reliable, cost-effective and digitally enabled point-of-care in vitro diagnostic system for early Alzheimer's disease detection. The 2D-BioPAD system will make use of cutting-edge 2D materials (i.e., graphene), nanomaterials and aptamers, to enhance biocompatibility, sensitivity and specificity for the simultaneous detection of up to five Alzheimer’s biomarkers in blood. The device will be accompanied by a user-friendly mobile app that will give healthcare professionals real-time access to quantified results in primary healthcare settings. Along the way, artificial intelligence will be used to optimize the design and implementation of the 2D-BioPAD system.

Read the full story Posted: Oct 20,2023

Researchers develop graphene-based wearable patch for continuous analysis of biomarkers in sweat

A team of researchers at Penn State has reported the design and fabrication of a long-term stable and highly sensitive flexible electrochemical sensor based on nanocomposite-modified porous graphene by facile laser treatment for detecting biomarkers such as glucose in sweat. 

The laser-reduced and patterned stable conductive nanocomposite on the porous graphene electrode provides the resulting glucose sensor with an excellent sensitivity of 1317.69 µA mm−1 cm−2 and an ultra-low limit of detection of 0.079 µm. The sensor can also detect pH and exhibit extraordinary stability to maintain more than 91% sensitivity over 21 days in ambient conditions. Taken together with a temperature sensor based on the same material system, the dual glucose and pH sensor integrated with a flexible microfluidic sweat sampling network further results in accurate continuous on-body glucose detection calibrated by the simultaneously measured pH and temperature. 

Read the full story Posted: Oct 01,2023

Researchers report GO-based composite fibers as artificial muscles

Researchers at the University of Pennsylvania have fabricated meter-long composite fibers combining graphene oxide (GO) nanosheets with flexible, conductive polymers that can achieve mechanical strength, toughness, and actuation that surpasses biological muscles.

The team wet-spin a mixture of GO nanosheets and poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT: PSS) into a composite fiber in which the flexible, conductive polymer is embedded in between aligned, closely-packed nanosheets. The addition of a depleting agent, polyethylene glycol (PEG), improves toughness and elasticity, while chemical reduction of GO to rGO increases electrical conductivity. Finally, the composite fibers are plied with nylon yarns to create a hierarchical composite actuator with capabilities better than typical biological muscles (75 J/kg work capacity and 924 W/kg power density).

Read the full story Posted: Sep 26,2023

INBRAIN Neuroelectronics announces FDA Breakthrough Device Designation for Its Graphene-Based Intelligent Network Modulation Platform

INBRAIN Neuroelectronics, a health-tech company dedicated to developing intelligent graphene-neural platform, has announced that its Intelligent Network Modulation System has been granted Breakthrough Device Designation (BDD) from the U.S. Food & Drug Administration (FDA) as an adjunctive therapy for treating Parkinson’s disease.

The INBRAIN system uses graphene, whose electrical and mechanical properties make it ideal for neurotechnology innovation. INBRAIN’s neural platform technology enables ultra-high signal resolution and uses machine learning software that decodes therapy-specific biomarkers to deliver highly focused, adaptive neuroelectronic therapy that re-balances pathological neural networks.

Read the full story Posted: Sep 20,2023

Researchers design scalable graphene sensor array for real-time toxins monitoring in flowing water

A team of researchers, led by the University of Wisconsin-Milwaukee, recently developed a path to mass-manufacture high-performance graphene sensors that can detect heavy metals and bacteria in flowing tap water. This advance could bring down the cost of such sensors to just US $1 each, allowing people to test their drinking water for toxins at home.

The sensors have to be extraordinarily sensitive to catch the minute concentrations of toxins that can cause harm. For example, the U.S. Food and Drug Administration states that bottled water must have a lead concentration of no more than 5 parts per billion. Today, detecting parts-per-billion or even parts-per-trillion concentrations of heavy metals, bacteria, and other toxins is only possible by analyzing water samples in the laboratory, says Junhong Chen, a professor of molecular engineering at the University of Chicago and the lead water strategist at Argonne National Laboratory. But his group has developed a sensor with a graphene field-effect transistor (FET) that can detect toxins at those low levels within seconds.

Read the full story Posted: Aug 29,2023